JP2012529522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012529522A5 JP2012529522A5 JP2012515069A JP2012515069A JP2012529522A5 JP 2012529522 A5 JP2012529522 A5 JP 2012529522A5 JP 2012515069 A JP2012515069 A JP 2012515069A JP 2012515069 A JP2012515069 A JP 2012515069A JP 2012529522 A5 JP2012529522 A5 JP 2012529522A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pyrazol
- carboxamide
- bicyclo
- pyrimidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 159
- -1 cyano, nitro, hydroxy, amino Chemical group 0.000 claims description 104
- 229910052736 halogen Inorganic materials 0.000 claims description 26
- 150000002367 halogens Chemical class 0.000 claims description 26
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 16
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 8
- 125000004366 heterocycloalkenyl group Chemical group 0.000 claims description 6
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 229910052794 bromium Inorganic materials 0.000 claims description 4
- 125000000623 heterocyclic group Chemical group 0.000 claims description 4
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- ZTUUVDYQBLRAAC-UHFFFAOYSA-N bicyclo[2.2.1]hept-2-ene-5-carboxamide Chemical compound C1C2C(C(=O)N)CC1C=C2 ZTUUVDYQBLRAAC-UHFFFAOYSA-N 0.000 claims 50
- PFXXTYUSZRFQHC-UHFFFAOYSA-N 2-methylhept-5-enamide Chemical compound CC=CCCC(C)C(N)=O PFXXTYUSZRFQHC-UHFFFAOYSA-N 0.000 claims 40
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 33
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 21
- DEOUZFWSQWEPGE-UHFFFAOYSA-N 2-methylheptanamide Chemical compound CCCCCC(C)C(N)=O DEOUZFWSQWEPGE-UHFFFAOYSA-N 0.000 claims 12
- SLOPJPLJISGXPG-UHFFFAOYSA-N bicyclo[2.2.1]heptane-3-carboxamide Chemical compound C1CC2C(C(=O)N)CC1C2 SLOPJPLJISGXPG-UHFFFAOYSA-N 0.000 claims 7
- XRLDSWLMHUQECH-UHFFFAOYSA-N cyclopentanecarboxamide Chemical compound NC(=O)C1CCCC1 XRLDSWLMHUQECH-UHFFFAOYSA-N 0.000 claims 6
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 5
- 150000003839 salts Chemical class 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- QDXGKRWDQCEABB-UHFFFAOYSA-N pyrimidine-5-carboxamide Chemical compound NC(=O)C1=CN=CN=C1 QDXGKRWDQCEABB-UHFFFAOYSA-N 0.000 claims 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- OMCDXKNVARSHIM-XXSPCDMZSA-N (1r,2s,3r,4s)-3-[[2-[(1-ethylpyrazol-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]bicyclo[2.2.1]heptane-2-carboxamide Chemical compound N([C@H]1[C@H]([C@]2([H])CC[C@]1(C2)[H])C(N)=O)C(C(=CN=1)C(F)(F)F)=NC=1NC=1C=NN(CC)C=1 OMCDXKNVARSHIM-XXSPCDMZSA-N 0.000 claims 2
- FYGUSUBEMUKACF-UHFFFAOYSA-N bicyclo[2.2.1]hept-2-ene-5-carboxylic acid Chemical compound C1C2C(C(=O)O)CC1C=C2 FYGUSUBEMUKACF-UHFFFAOYSA-N 0.000 claims 2
- MFNYBOWJWGPXFM-UHFFFAOYSA-N cyclobutanecarboxamide Chemical compound NC(=O)C1CCC1 MFNYBOWJWGPXFM-UHFFFAOYSA-N 0.000 claims 2
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- ABKPYKYMAYCYSR-DRABBMOASA-N (1r,2r,3s,4s)-3-[[5-bromo-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@@H]1[C@@H]([C@]2([H])C[C@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)Br)=NC=1NC=1C=NN(CC)C=1 ABKPYKYMAYCYSR-DRABBMOASA-N 0.000 claims 1
- CWGMUGAHFWGINC-PJQZNRQZSA-N (1r,2r,3s,4s)-3-[[5-bromo-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@@H]1[C@@H]([C@]2([H])C[C@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)Br)=NC=1NC=1C=NN(C)C=1 CWGMUGAHFWGINC-PJQZNRQZSA-N 0.000 claims 1
- GWAODKLMHUOUEN-DRABBMOASA-N (1r,2r,3s,4s)-3-[[5-chloro-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@@H]1[C@@H]([C@]2([H])C[C@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CC)C=1 GWAODKLMHUOUEN-DRABBMOASA-N 0.000 claims 1
- UWJZCHZNTUYAIM-PJQZNRQZSA-N (1r,2r,3s,4s)-3-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@@H]1[C@@H]([C@]2([H])C[C@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 UWJZCHZNTUYAIM-PJQZNRQZSA-N 0.000 claims 1
- WHDZRHLPGYRKOD-MDSNHJATSA-N (1r,2r,3s,4s)-3-[[5-fluoro-2-(1h-pyrazol-4-ylamino)pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@@H]1[C@@H]([C@]2([H])C[C@]1(C=C2)[H])C(N)=O)C(C(=CN=1)F)=NC=1NC=1C=NNC=1 WHDZRHLPGYRKOD-MDSNHJATSA-N 0.000 claims 1
- MNGDJFQVLRLXMO-PJQZNRQZSA-N (1r,2r,3s,4s)-3-[[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@@H]1[C@@H]([C@]2([H])C[C@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)F)=NC=1NC=1C=NN(C)C=1 MNGDJFQVLRLXMO-PJQZNRQZSA-N 0.000 claims 1
- XMAWJUOJKHIGND-XQHKEYJVSA-N (1r,2s,3r,4s)-3-[[5-chloro-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound N([C@@H]1[C@@H]([C@@]2([H])CC[C@@]1(O2)[H])C(N)=O)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CC)C=1 XMAWJUOJKHIGND-XQHKEYJVSA-N 0.000 claims 1
- SCMNVDCXNVNNAF-KXNHARMFSA-N (1r,2s,3r,4s)-3-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound N([C@@H]1[C@@H]([C@@]2([H])CC[C@@]1(O2)[H])C(N)=O)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 SCMNVDCXNVNNAF-KXNHARMFSA-N 0.000 claims 1
- MBBPYWUJBMAFFE-NHULGOKLSA-N (1r,3s,4r,5r)-4-[[2-[(1-ethylpyrazol-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxamide Chemical compound N([C@@H]1[C@@]2(C[C@](C[C@@H]1C(N)=O)(C2(C)C)[H])[H])C(C(=CN=1)C(F)(F)F)=NC=1NC=1C=NN(CC)C=1 MBBPYWUJBMAFFE-NHULGOKLSA-N 0.000 claims 1
- KAUKYDYNYGPGFX-ASHKBJFXSA-N (1r,3s,4r,5r)-4-[[5-bromo-2-[(1,5-dimethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxamide Chemical compound N([C@@H]1[C@@]2(C[C@](C[C@@H]1C(N)=O)(C2(C)C)[H])[H])C(C(=CN=1)Br)=NC=1NC=1C=NN(C)C=1C KAUKYDYNYGPGFX-ASHKBJFXSA-N 0.000 claims 1
- AFZYWEXDYRWRIE-ASHKBJFXSA-N (1r,3s,4r,5r)-4-[[5-chloro-2-[(1,5-dimethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxamide Chemical compound N([C@@H]1[C@@]2(C[C@](C[C@@H]1C(N)=O)(C2(C)C)[H])[H])C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1C AFZYWEXDYRWRIE-ASHKBJFXSA-N 0.000 claims 1
- VNQSHTJHQRSLAG-RPZXMPESSA-N (1r,3s,4r,5r)-4-[[5-chloro-2-[(1-piperidin-4-ylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxamide Chemical compound N([C@@H]1[C@@]2(C[C@](C[C@@H]1C(N)=O)(C2(C)C)[H])[H])C(C(=CN=1)Cl)=NC=1NC(=C1)C=NN1C1CCNCC1 VNQSHTJHQRSLAG-RPZXMPESSA-N 0.000 claims 1
- QUBSSCKDMYODIH-WBKMXMRLSA-N (1r,3s,4r,5r)-4-[[5-chloro-2-[[1-(2-phenylethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxamide Chemical compound N([C@@H]1[C@@]2(C[C@](C[C@@H]1C(N)=O)(C2(C)C)[H])[H])C(C(=CN=1)Cl)=NC=1NC(=C1)C=NN1CCC1=CC=CC=C1 QUBSSCKDMYODIH-WBKMXMRLSA-N 0.000 claims 1
- WZHIWIPFGYQZMG-CAIZAGQASA-N (1r,3s,4r,5r)-4-[[5-chloro-2-[[1-[2-(4-methylpiperazin-1-yl)ethyl]pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-6,6-dimethylbicyclo[3.1.1]heptane-3-carboxamide Chemical compound N([C@@H]1[C@@]2(C[C@](C[C@@H]1C(N)=O)(C2(C)C)[H])[H])C(C(=CN=1)Cl)=NC=1NC(=C1)C=NN1CCN1CCN(C)CC1 WZHIWIPFGYQZMG-CAIZAGQASA-N 0.000 claims 1
- DJASEHPUPBAANK-PKOBYXMFSA-N (1s,2r)-2-[[5-chloro-2-[[1-(2-morpholin-4-ylethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]-n-propan-2-ylcyclopentane-1-carboxamide Chemical compound CC(C)NC(=O)[C@H]1CCC[C@H]1NC1=NC(NC2=CN(CCN3CCOCC3)N=C2)=NC=C1Cl DJASEHPUPBAANK-PKOBYXMFSA-N 0.000 claims 1
- XMAWJUOJKHIGND-QNWHQSFQSA-N (1s,2r,3s,4r)-3-[[5-chloro-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound N([C@H]1[C@H]([C@]2([H])CC[C@]1(O2)[H])C(N)=O)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CC)C=1 XMAWJUOJKHIGND-QNWHQSFQSA-N 0.000 claims 1
- SCMNVDCXNVNNAF-WHOHXGKFSA-N (1s,2r,3s,4r)-3-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-7-oxabicyclo[2.2.1]heptane-2-carboxamide Chemical compound N([C@H]1[C@H]([C@]2([H])CC[C@]1(O2)[H])C(N)=O)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 SCMNVDCXNVNNAF-WHOHXGKFSA-N 0.000 claims 1
- ABKPYKYMAYCYSR-FDRIWYBQSA-N (1s,2s,3r,4r)-3-[[5-bromo-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)Br)=NC=1NC=1C=NN(CC)C=1 ABKPYKYMAYCYSR-FDRIWYBQSA-N 0.000 claims 1
- CWGMUGAHFWGINC-XXSPCDMZSA-N (1s,2s,3r,4r)-3-[[5-bromo-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)Br)=NC=1NC=1C=NN(C)C=1 CWGMUGAHFWGINC-XXSPCDMZSA-N 0.000 claims 1
- VXPDAIADPMQBBR-GIYDNNGJSA-N (1s,2s,3r,4r)-3-[[5-bromo-2-[[1-(2-phenylethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)Br)=NC=1NC(=C1)C=NN1CCC1=CC=CC=C1 VXPDAIADPMQBBR-GIYDNNGJSA-N 0.000 claims 1
- GWAODKLMHUOUEN-FDRIWYBQSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CC)C=1 GWAODKLMHUOUEN-FDRIWYBQSA-N 0.000 claims 1
- UWJZCHZNTUYAIM-XXSPCDMZSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)Cl)=NC=1NC=1C=NN(C)C=1 UWJZCHZNTUYAIM-XXSPCDMZSA-N 0.000 claims 1
- KABAZFRNMIEGAI-GIYDNNGJSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[[1-(2-phenylethyl)pyrazol-4-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)Cl)=NC=1NC(=C1)C=NN1CCC1=CC=CC=C1 KABAZFRNMIEGAI-GIYDNNGJSA-N 0.000 claims 1
- PGBNFIBSIHDVLJ-GIYDNNGJSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[[1-[(3-methylphenyl)methyl]pyrazol-4-yl]amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)Cl)=NC=1NC(=C1)C=NN1CC1=CC=CC(C)=C1 PGBNFIBSIHDVLJ-GIYDNNGJSA-N 0.000 claims 1
- WHDZRHLPGYRKOD-UFGYURQFSA-N (1s,2s,3r,4r)-3-[[5-fluoro-2-(1h-pyrazol-4-ylamino)pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)F)=NC=1NC=1C=NNC=1 WHDZRHLPGYRKOD-UFGYURQFSA-N 0.000 claims 1
- MNGDJFQVLRLXMO-XXSPCDMZSA-N (1s,2s,3r,4r)-3-[[5-fluoro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]-n-methylbicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(=O)NC)C(C(=CN=1)F)=NC=1NC=1C=NN(C)C=1 MNGDJFQVLRLXMO-XXSPCDMZSA-N 0.000 claims 1
- 125000004529 1,2,3-triazinyl group Chemical group N1=NN=C(C=C1)* 0.000 claims 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 1
- YWZGAGXMSIOYIX-UHFFFAOYSA-N 1-[2-[[2-[(1-methylpyrazol-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]cyclobutan-1-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(C(F)(F)F)C(NC=2C(=CC=CC=2)C2(O)CCC2)=N1 YWZGAGXMSIOYIX-UHFFFAOYSA-N 0.000 claims 1
- ACEMPAATJHNUIT-UHFFFAOYSA-N 1-[2-[[5-bromo-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]phenyl]cyclobutan-1-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(Br)C(NC=2C(=CC=CC=2)C2(O)CCC2)=N1 ACEMPAATJHNUIT-UHFFFAOYSA-N 0.000 claims 1
- FUVCKJYFOFPYSZ-UHFFFAOYSA-N 1-[2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]phenyl]cyclobutan-1-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC=2C(=CC=CC=2)C2(O)CCC2)=N1 FUVCKJYFOFPYSZ-UHFFFAOYSA-N 0.000 claims 1
- CKTOGCUGKAJSJR-UHFFFAOYSA-N 1-methyl-4-[[2-[(1-methylpyrazol-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]pyrazole-3-carboxamide Chemical compound C1=NN(C)C=C1NC1=NC=C(C(F)(F)F)C(NC=2C(=NN(C)C=2)C(N)=O)=N1 CKTOGCUGKAJSJR-UHFFFAOYSA-N 0.000 claims 1
- UIDWSNOOPHGNAG-UHFFFAOYSA-N 2-[2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]phenyl]propan-2-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC=2C(=CC=CC=2)C(C)(C)O)=N1 UIDWSNOOPHGNAG-UHFFFAOYSA-N 0.000 claims 1
- QYQLAHVYGBJXDH-OBPYKSBLSA-N 2-[4-[[4-[[(1s,2s,3r,4r)-2-carbamoyl-3-bicyclo[2.2.1]hept-5-enyl]amino]-5-chloropyrimidin-2-yl]amino]pyrazol-1-yl]acetic acid Chemical compound N([C@H]1[C@H]([C@@]2([H])C[C@@]1(C=C2)[H])C(N)=O)C(C(=CN=1)Cl)=NC=1NC=1C=NN(CC(O)=O)C=1 QYQLAHVYGBJXDH-OBPYKSBLSA-N 0.000 claims 1
- LXUZDUJAEODFJS-UHFFFAOYSA-N 2-[4-[[5-chloro-4-(1h-indazol-5-ylamino)pyrimidin-2-yl]amino]pyrazol-1-yl]ethanol Chemical compound C1=NN(CCO)C=C1NC1=NC=C(Cl)C(NC=2C=C3C=NNC3=CC=2)=N1 LXUZDUJAEODFJS-UHFFFAOYSA-N 0.000 claims 1
- HYNAMEOYEGNYAC-UHFFFAOYSA-N 3-[2-[[2-[(1-methylpyrazol-4-yl)amino]-5-(trifluoromethyl)pyrimidin-4-yl]amino]phenyl]azetidin-3-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(C(F)(F)F)C(NC=2C(=CC=CC=2)C2(O)CNC2)=N1 HYNAMEOYEGNYAC-UHFFFAOYSA-N 0.000 claims 1
- ZOFMFMNMMNYFRG-UHFFFAOYSA-N 4-[2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]phenyl]oxan-4-ol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC=2C(=CC=CC=2)C2(O)CCOCC2)=N1 ZOFMFMNMMNYFRG-UHFFFAOYSA-N 0.000 claims 1
- NWXWUGBTGKLUSJ-UHFFFAOYSA-N 5-bromo-2-n-(1-ethylpyrazol-4-yl)-2-n-(1h-indazol-5-yl)pyrimidine-2,4-diamine Chemical compound C1=NN(CC)C=C1N(C=1N=C(N)C(Br)=CN=1)C1=CC=C(NN=C2)C2=C1 NWXWUGBTGKLUSJ-UHFFFAOYSA-N 0.000 claims 1
- IUIGCIYQEQMDLR-UHFFFAOYSA-N 5-chloro-2-n-(1-ethylpyrazol-4-yl)-4-n-(1h-indazol-5-yl)pyrimidine-2,4-diamine Chemical compound C1=NN(CC)C=C1NC1=NC=C(Cl)C(NC=2C=C3C=NNC3=CC=2)=N1 IUIGCIYQEQMDLR-UHFFFAOYSA-N 0.000 claims 1
- CQGUJQNQCRSZMD-UHFFFAOYSA-N 5-chloro-2-n-(1h-indazol-5-yl)-2-n-[1-(2-pyrrolidin-1-ylethyl)pyrazol-4-yl]pyrimidine-2,4-diamine Chemical compound C1=C(Cl)C(N)=NC(N(C2=CN(CCN3CCCC3)N=C2)C=2C=C3C=NNC3=CC=2)=N1 CQGUJQNQCRSZMD-UHFFFAOYSA-N 0.000 claims 1
- DMHIOKGPIMIGBU-CYBMUJFWSA-N 5-chloro-2-n-(1h-indazol-5-yl)-2-n-[1-[(3r)-pyrrolidin-3-yl]pyrazol-4-yl]pyrimidine-2,4-diamine Chemical compound C1=C(Cl)C(N)=NC(N(C2=CN(N=C2)[C@H]2CNCC2)C=2C=C3C=NNC3=CC=2)=N1 DMHIOKGPIMIGBU-CYBMUJFWSA-N 0.000 claims 1
- BHNOJVWXPAIWCZ-UHFFFAOYSA-N 5-chloro-2-n-(1h-indazol-5-yl)-2-n-[1-[2-(4-methylpiperazin-1-yl)ethyl]pyrazol-4-yl]pyrimidine-2,4-diamine Chemical compound C1CN(C)CCN1CCN1N=CC(N(C=2C=C3C=NNC3=CC=2)C=2N=C(N)C(Cl)=CN=2)=C1 BHNOJVWXPAIWCZ-UHFFFAOYSA-N 0.000 claims 1
- OHIIDHVAVXSMDA-UHFFFAOYSA-N 5-chloro-4-n-(1h-indazol-5-yl)-2-n-(1-methylpyrazol-4-yl)pyrimidine-2,4-diamine Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC=2C=C3C=NNC3=CC=2)=N1 OHIIDHVAVXSMDA-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010014733 Endometrial cancer Diseases 0.000 claims 1
- 206010014759 Endometrial neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- CRBHUUMFIXCJNV-UHFFFAOYSA-N [2-[[5-chloro-2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]amino]phenyl]methanol Chemical compound C1=NN(C)C=C1NC1=NC=C(Cl)C(NC=2C(=CC=CC=2)CO)=N1 CRBHUUMFIXCJNV-UHFFFAOYSA-N 0.000 claims 1
- 125000002393 azetidinyl group Chemical group 0.000 claims 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- AZZRVUPMYALVJF-UHFFFAOYSA-N bicyclo[3.1.1]heptane-3-carboxamide Chemical compound C12CC(CC(C1)C2)C(=O)N AZZRVUPMYALVJF-UHFFFAOYSA-N 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- VSCLUBLXOWRBCQ-UHFFFAOYSA-N cyclohex-3-ene-1-carboxamide Chemical compound NC(=O)C1CCC=CC1 VSCLUBLXOWRBCQ-UHFFFAOYSA-N 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000005412 pyrazyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- DENPQNAWGQXKCU-UHFFFAOYSA-N thiophene-2-carboxamide Chemical compound NC(=O)C1=CC=CS1 DENPQNAWGQXKCU-UHFFFAOYSA-N 0.000 claims 1
- DAUYIKBTMNZABP-UHFFFAOYSA-N thiophene-3-carboxamide Chemical compound NC(=O)C=1C=CSC=1 DAUYIKBTMNZABP-UHFFFAOYSA-N 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 *c1c(*)nc(Nc2c[n](*)nc2)nc1N[Al] Chemical compound *c1c(*)nc(Nc2c[n](*)nc2)nc1N[Al] 0.000 description 9
- KRRABBSJRIDMAG-UHFFFAOYSA-N CC(C1)C2OC1CC=C2 Chemical compound CC(C1)C2OC1CC=C2 KRRABBSJRIDMAG-UHFFFAOYSA-N 0.000 description 1
- FQOYMFBTGPHRJQ-UHFFFAOYSA-N CC1C(C2)OC2C1 Chemical compound CC1C(C2)OC2C1 FQOYMFBTGPHRJQ-UHFFFAOYSA-N 0.000 description 1
- YSPMLGNTRGMJLE-UHFFFAOYSA-N CC1C(CC2)OC2C1 Chemical compound CC1C(CC2)OC2C1 YSPMLGNTRGMJLE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18575809P | 2009-06-10 | 2009-06-10 | |
| US61/185,758 | 2009-06-10 | ||
| PCT/US2010/037801 WO2010144468A1 (en) | 2009-06-10 | 2010-06-08 | 2- ( lh-pyrazol-4 -ylamino ) -pyrimidine as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012529522A JP2012529522A (ja) | 2012-11-22 |
| JP2012529522A5 true JP2012529522A5 (OSRAM) | 2013-04-18 |
Family
ID=42333314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012515069A Ceased JP2012529522A (ja) | 2009-06-10 | 2010-06-08 | キナーゼ阻害剤としての２−（１ｈ−ピラゾール−４−イルアミノ）−ピリミジン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8426408B2 (OSRAM) |
| EP (1) | EP2440548A1 (OSRAM) |
| JP (1) | JP2012529522A (OSRAM) |
| CN (1) | CN102498110A (OSRAM) |
| CA (1) | CA2764983A1 (OSRAM) |
| MX (1) | MX2011013325A (OSRAM) |
| WO (1) | WO2010144468A1 (OSRAM) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2012014158A (es) | 2010-06-04 | 2013-02-07 | Hoffmann La Roche | Derivados de aminopirimidina como moduladores de proteina cinasa rica repeticiones leucina 2 (lrrk2). |
| ES2653967T3 (es) * | 2010-11-10 | 2018-02-09 | Genentech, Inc. | Derivados de pirazol aminopirimidina como moduladores de LRRK2 |
| PE20140502A1 (es) * | 2011-04-22 | 2014-05-02 | Signal Pharm Llc | Pirimidinas sustituidas de diaminocarboxamida y diaminocarbonitrilo, composiciones de las mismas y metodos de tratamiento con las mismas |
| MX363118B (es) * | 2012-05-03 | 2019-03-11 | Genentech Inc | Derivados de pirazol aminopirimidina como moduladores de cinasa 2 de repeticion rica en leucina (lrrk2). |
| US9724354B2 (en) | 2013-03-22 | 2017-08-08 | Millennium Pharmaceuticals, Inc. | Combination of catalytic mTORC1/2 inhibitors and selective inhibitors of Aurora A kinase |
| US10273224B2 (en) | 2013-08-22 | 2019-04-30 | Jubilant Biosys Limited | Substituted pyrimidine compounds, compositions and medicinal applications thereof |
| WO2015039613A1 (zh) * | 2013-09-18 | 2015-03-26 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
| NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
| CN104926794B (zh) * | 2014-03-17 | 2017-12-05 | 广东东阳光药业有限公司 | 取代的杂芳基化合物及其组合物和用途 |
| WO2015148868A1 (en) * | 2014-03-28 | 2015-10-01 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| US10059689B2 (en) | 2014-10-14 | 2018-08-28 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
| JP6903577B2 (ja) | 2014-12-16 | 2021-07-14 | シグナル ファーマシューティカルズ，エルエルシー | 皮膚におけるｃ−Ｊｕｎ Ｎ末端キナーゼの阻害の測定方法 |
| BR112017012795A2 (pt) | 2014-12-16 | 2018-01-02 | Signal Pharmaceuticals, Llc | Formulações de 2-(terc-butilamino)-4-((1r,3r,4r)-3- hidroxi-4-metilciclo-hexilamino)-pirimidina-5- carboxamida |
| CA2975260C (en) | 2015-01-29 | 2024-05-21 | Signal Pharmaceuticals Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
| MX2018001004A (es) | 2015-07-24 | 2018-06-07 | Celgene Corp | Metodos de sintesis de clorhidrato de (1r,2r,5r)-5-amino-2-metilci clohexanol e intermedios utiles en este. |
| WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
| JP2018527381A (ja) * | 2015-09-17 | 2018-09-20 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換されたヘテロアリール化合物および使用方法 |
| CN106588885B (zh) * | 2016-11-10 | 2019-03-19 | 浙江大学 | 2-取代芳环-嘧啶类衍生物及制备和应用 |
| EP3710006A4 (en) | 2017-11-19 | 2021-09-01 | Sunshine Lake Pharma Co., Ltd. | SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE |
| CN110862376A (zh) * | 2019-10-24 | 2020-03-06 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| TW202237119A (zh) | 2020-12-10 | 2022-10-01 | 美商住友製藥腫瘤公司 | Ａｌｋ﹘５抑制劑和彼之用途 |
| CN118546132A (zh) * | 2023-02-27 | 2024-08-27 | 科辉智药(深圳)新药研究中心有限公司 | 亚砜酰亚胺化合物及其作为lrrk2蛋白激酶抑制剂的应用 |
| CN118440052B (zh) * | 2024-07-05 | 2024-10-11 | 四川大学 | 一种化合物及其在制备tyk2激酶抑制剂中的用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5374301A (en) | 1990-07-26 | 1994-12-20 | Zeneca Limited | Inks suitable for use in ink jet printing |
| GB9303912D0 (en) | 1993-02-26 | 1993-04-14 | Zeneca Ltd | Inks |
| JP3880076B2 (ja) | 1994-02-25 | 2007-02-14 | キヤノン株式会社 | インク、インクジェット記録方法、記録ユニット、インクカートリッジ及びインクジェット記録装置 |
| JPH08113744A (ja) | 1994-08-25 | 1996-05-07 | Canon Inc | インク、これを用いたインクジェット記録方法及びかかるインクを備えた記録機器 |
| US6117996A (en) | 1995-09-20 | 2000-09-12 | Novo Nordisk A/S | Triazine based ligands and use thereof |
| GB9519197D0 (en) | 1995-09-20 | 1995-11-22 | Affinity Chromatography Ltd | Novel affinity ligands and their use |
| JP3106966B2 (ja) | 1996-07-17 | 2000-11-06 | 富士ゼロックス株式会社 | インクジェット記録用インク及びインクジェット記録方法 |
| JPH1060338A (ja) | 1996-08-21 | 1998-03-03 | Fuji Xerox Co Ltd | インクジェット記録用インク及びインクジェット記録方法 |
| US5980623A (en) | 1997-01-29 | 1999-11-09 | Fuji Xerox Co., Ltd. | Ink set for ink jet recording and ink jet recording method |
| JP3829419B2 (ja) | 1997-07-09 | 2006-10-04 | 三菱化学株式会社 | カラー画像の形成方法 |
| EP1058549A4 (en) | 1998-12-23 | 2003-11-12 | Bristol Myers Squibb Pharma Co | FACTOR Xa OR THROMBIN INHIBITORS |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| JP4607879B2 (ja) * | 2003-08-15 | 2011-01-05 | ノバルティス アーゲー | 新生物疾患、炎症および免疫障害の処置に有用な２，４−ピリミジンジアミン |
| JP4812763B2 (ja) | 2004-05-18 | 2011-11-09 | ライジェル ファーマシューティカルズ， インコーポレイテッド | シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途 |
| CA2585934C (en) | 2004-10-29 | 2013-09-10 | Abbott Laboratories | Novel pyrazolopyridine urea kinase inhibitors |
| GB2420559B (en) | 2004-11-15 | 2008-08-06 | Rigel Pharmaceuticals Inc | Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| WO2006055831A2 (en) * | 2004-11-17 | 2006-05-26 | Miikana Therapeutics, Inc. | Kinase inhibitors |
| US8211929B2 (en) * | 2004-12-30 | 2012-07-03 | Exelixis, Inc. | Pyrimidine derivatives as kinase modulators and method of use |
| JPWO2006126718A1 (ja) | 2005-05-27 | 2008-12-25 | 田辺三菱製薬株式会社 | ピラゾロピリミジン誘導体 |
| RU2485106C2 (ru) | 2005-06-08 | 2013-06-20 | Райджел Фамэсьютикэлз, Инк. | Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений |
| CA2611734A1 (en) | 2005-06-10 | 2006-12-14 | Prometic Biosciences Limited | Triazines as protein binding ligands |
| US20070032514A1 (en) | 2005-07-01 | 2007-02-08 | Zahn Stephan K | 2,4-diamino-pyrimidines as aurora inhibitors |
| WO2008147831A1 (en) * | 2007-05-23 | 2008-12-04 | Smithkline Beecham Corporation | Anthranilamides |
-
2010
- 2010-06-08 CA CA2764983A patent/CA2764983A1/en not_active Abandoned
- 2010-06-08 MX MX2011013325A patent/MX2011013325A/es active IP Right Grant
- 2010-06-08 CN CN2010800358308A patent/CN102498110A/zh active Pending
- 2010-06-08 WO PCT/US2010/037801 patent/WO2010144468A1/en not_active Ceased
- 2010-06-08 JP JP2012515069A patent/JP2012529522A/ja not_active Ceased
- 2010-06-08 EP EP10724646A patent/EP2440548A1/en not_active Withdrawn
- 2010-06-09 US US12/796,751 patent/US8426408B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012529522A5 (OSRAM) | ||
| ES2601086T3 (es) | Compuestos de pirimidina útiles en el tratamiento de enfermedades mediadas por mecanismos de IKKépsilon y/o TBK1 | |
| JP6298115B2 (ja) | Ｌｒｒｋ２調節薬としてのピラゾールアミノピリミジン誘導体 | |
| KR101904632B1 (ko) | 2,4-이치환 페닐-1,5-디아민 유도체, 이의 응용, 및 이로 제조한 약물 조성물 | |
| ES2391757T3 (es) | Derivados de 1-H-pirrol sustituidos con 1-heterociclilsulfonilo, 2-aminometilo, 5-heteroarilo como inhibidores de la secreción de ácido | |
| DK2805940T3 (en) | PYRAZINE CARBOXAMIDE COMPOUND | |
| JP6635949B2 (ja) | 炎症性および自己免疫性の病気の処置のためのｍｔｈ１阻害剤 | |
| JP6923543B2 (ja) | Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール | |
| RU2693624C2 (ru) | Новое дизамещенное 1,2,4-триазиновое соединение | |
| JP6231085B2 (ja) | アミノキナゾリン誘導体及びピリドピリミジン誘導体 | |
| CN105121436B (zh) | 新的吡啶衍生物 | |
| JP2016523911A5 (OSRAM) | ||
| RU2021133444A (ru) | Производные бензимидазола в качестве модуляторов ror-гамма | |
| CN105143206A (zh) | 用于治疗癌症的嘧啶-2,4-二胺衍生物 | |
| JP2011503194A5 (OSRAM) | ||
| CN107344940B (zh) | Btk抑制剂及其用途 | |
| RU2016141088A (ru) | 5-замещённые индазол-3-карбоксамиды и их получение и применение | |
| ME02856B (me) | Aminopirimidinilni spojevi kao inhibitori jak | |
| JPWO2007114323A1 (ja) | アミノピロリジン化合物 | |
| JP6176244B2 (ja) | 芳香族複素環誘導体及び医薬 | |
| TW202430152A (zh) | 野生型ｋｉｔ抑制劑 | |
| US20250236608A1 (en) | Egfr inhibitors | |
| JP2023542724A (ja) | 造血前駆細胞キナーゼ１（ｈｐｋ１）阻害剤としてのインダゾールおよびその使用方法 | |
| EP4466259A1 (en) | New benzimidazole pyridine derivatives | |
| WO2019089512A1 (en) | Btk inhibitor compounds |